Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

Abstract Background Major prospective randomized clinical safety trials have demonstrated beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium–glucose co-transporter-2 inhibitors (SGLT-2i) in people with type 2 diabetes and elevated cardiovascular risk,...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Moa Lugner, Naveed Sattar, Mervete Miftaraj, Jan Ekelund, Stefan Franzén, Ann-Marie Svensson, Björn Eliasson
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2021-03-01
Edice:	Cardiovascular Diabetology
Témata:	Type 2 diabetes Epidemiology Sodium glucose transporter 2 inhibitors Glucagon‐like peptide-1 receptor agonist Mortality Cardiovascular disease
On-line přístup:	https://doi.org/10.1186/s12933-021-01258-x
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!